Your session is about to expire
← Back to Search
PVX-410 + Pembrolizumab for Advanced Breast Cancer
Study Summary
This trial is studying whether a combination of PVX-410, pembrolizumab, Hiltonol, and Montanide can help to treat triple-negative breast cancer that has spread to other parts of the body and cannot be removed by surgery.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My DNA test shows I am HLA A2 positive.I have cancer that has spread to my brain or spinal cord.I have an immune system disorder or have been on steroids or other immune-weakening medicines in the last week.I am fully active or can carry out light work.My organs and bone marrow are functioning well.I am a woman aged 18 or older.My breast cancer is advanced, cannot be removed by surgery, and meets certain criteria.I have been treated with drugs targeting PD-1, PD-L1, or PD-L2.You are willing to provide a sample of your stored tissue for additional research.You have received an organ from someone else in the past.You do not have HIV, hepatitis B, or hepatitis C.I have had at least one treatment for my breast cancer that has spread or come back.I have an active Tuberculosis infection.I have an autoimmune disease treated with medication in the last 2 years.I received my last dose of treatment within the required timeframe.I have had lung inflammation treated with steroids.My cancer has a type known for better outcomes.I don't have any health issues that could affect the study's results.I have another cancer that is getting worse or needs treatment.I am currently undergoing or planning to start cancer treatment soon.I have not received a live vaccine in the last 30 days.You have a disease that can be measured using a specific set of guidelines called RECIST 1.1.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What conditions have been addressed with the use of Pembrolizumab?
"Pembrolizumab has been known to effectively treat malignant tumours, irremediable melanoma, and microsatellite instabilities of high levels."
Is participation in this research endeavor open to new volunteers?
"According to clinicaltrials.gov, the call for participants in this medical trial has ended; initial posting was on December 12th 2017 and the final edit occured on May 6th 2021. Despite its closure, there are 3,324 other trials actively recruiting candidates at this time."
Are there any safety risks associated with Pembrolizumab for patients?
"Due to the early stage of this clinical trial, there is only scant evidence backing Pembrolizumab's safety and efficacy. Because of that, our team has assigned it a rating of 1 out of 3 on the scale."
What is the sample size of this trial?
"This research project is currently closed and no longer accepting participants. Despite the study being initially posted on December 12th of 2017, it was last altered on May 6th 2021. Alternatively, 2361 medical studies are actively recruiting patients with triple negative breast neoplasms while 963 trials for Pembrolizumab remain open to enrollment."
What other analyses have been conducted to assess the effectiveness of Pembrolizumab?
"Currently, there are 963 ongoing clinical trials for Pembrolizumab. Of these studies, 122 have progressed to the third phase of testing. Despite most research originating from Houston, Texas, there is a wide network of 35772 trial sites operating across the world."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger